AusperBio
Business Services · California, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
950 Tower Ln Ste 340, Foster City, Calif...Phone Number
(650) 888-1756Website
www.ausperbio.comRevenue
$33.8 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About AusperBio
AusperBio is a clinical-stage biopharmaceutical company with operations in the USA and China, dedicated to advancing oligonucleotide and targeted delivery technologies for transformative therapies, with an initial focus on achieving functional cure for chronic hepatitis B infection. The company has developed a proprietary Med-Oligo ASO platform which has been shown to substantially enhance the current ASO therapeutics, through novel insights into ASO design. Combining with efficient targeted delivery conjugation technologies, the modular Med-Oligo Platform empowers ASO therapeutics to treat a broad range of diseases, including viral infections, metabolic conditions, genetic disorders, and immune diseases.Explore more
AusperBio Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is AusperBio your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if AusperBio has recently received funding, and reach out quickly before it becomes old news!
Check out if AusperBio is spiking on competitors!
AusperBio, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at AusperBio
Earning: See what the market has to say on AusperBio recently announced quarterly report
Click to see if AusperBio had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when AusperBio launches new products
Funding: Get notified immidiatlly once AusperBio has new funding data
Recommended Actions
Reach out to Masked Content who joined AusperBio as Masked Content
Find 2 more new buyers
Company Profile Activity
Activity Insights
AusperBio is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
AusperBio is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about AusperBio.
AusperBio financials insights
Gather financial insights about AusperBio, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2024
Series A
$37M
2025
Other Financing Round
$50M
Series B
$123M
2026
Series C
$120M
Most Recent Scoops
Funding
Funding
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Funding
Funding
AusperBio News & Media
AusperBio Announces First Patient Dosed in Clinical Study of Investigational HBV Candidate AHB-171
SAN FRANCISCO, Aug. 3, 2026 /PRNewswire/ -- AusperBio Therapeutics Inc. and Ausper Biopharma Co., Ltd. (together AusperBio), a near-commercial Biopharmaceutical company focused on developing targeted oligonucleotide therapeutics for the treatment of chronic hepatitis B (CHB) and other...AusperBio concludes enrolment in Phase III AUSHINE trial
AHB-137 is an unconjugated antisense oligonucleotide developed using AusperBio's Med-Oligo platform.AusperBio Completes Patient Enrollment in Phase III AUSHINE Study of AHB-137 for Chronic Hepatitis B
SAN FRANCISCO, Dec. 22, 2025 /PRNewswire/ -- AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. (together AusperBio), a clinical-stage biotechnology company developing targeted oligonucleotide therapies for functional cure of chronic hepatitis B (CHB), today announced the...AusperBio Announces AHB-137 Monotherapy Achieved 30% Functional Cure Rate in HBe-negative CHB Patients on Stable Nucleos(t)ide Analogue (NA) Therapy
SAN FRANCISCO, Dec. 12, 2025 /PRNewswire/ -- AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. (together AusperBio), a clinical-stage biotechnology company developing oligonucleotide-based therapies for functional cure of chronic hepatitis B (CHB), today announced full...
Read more news
Top Business Services Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding AusperBio
Sign Up For FreeTo access detailed company insights
AusperBio is a clinical-stage biopharmaceutical company with operations in the USA and China, dedicated to advancing oligonucleotide and targeted delivery technologies for transformative therapies, with an initial focus on achieving functional cure for chronic hepatitis B infection. The company has developed a proprietary Med-Oligo ASO platform whi... Read More
